Skip to main content
Log in

Latest Updates on Lipid Management

  • Review article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. Despite the clinical long-term and near-term benefits of lowering cholesterol in, respectively, primary and secondary prevention of ASCVD, cholesterol levels remain under-treated, with many patients not achieving their recommended targets. The present article will review the latest updates on lipid management with emphases on the different classes of cholesterol-lowering agents and their clinical uses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1–10.

    PubMed  Google Scholar 

  2. WHO. Cardiovascular diseases (CVDs). WHO 2017. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 16 Aug 2017.

  3. Alonge VO, Grant T, Drummond A, Sugrue D, Codd M. Cardiovascular disease burden in acute public hospitals in Ireland: estimates for 2021 and 2031. Ir J Med Sci. 2013;182:245–53.

    Article  CAS  PubMed  Google Scholar 

  4. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.

    PubMed  Google Scholar 

  5. Anderson KM, Castelli WP, Levcy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–80.

    Article  CAS  PubMed  Google Scholar 

  6. Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality. A 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512–9.

    Article  CAS  PubMed  Google Scholar 

  7. Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol. 2012;2012:1–7.

    Article  CAS  Google Scholar 

  8. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.

    Article  CAS  PubMed  Google Scholar 

  9. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.

    Article  CAS  PubMed  Google Scholar 

  10. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, INTERHEART Study Investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet. 2008;372:224–33.

    Article  CAS  PubMed  Google Scholar 

  11. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–22.

    Article  CAS  PubMed  Google Scholar 

  12. Reiner Z. How to improve cardiovascular diseases prevention in Europe? Nutr Metab Cardiovasc Dis. 2009;19:451–4.

    Article  CAS  PubMed  Google Scholar 

  13. Rabar S, Harker M, O’Flynn N, Wierzbicki AS, Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356.

    Article  CAS  PubMed  Google Scholar 

  14. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569–78.

    Article  CAS  PubMed  Google Scholar 

  15. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009;169:659.

    Article  CAS  PubMed  Google Scholar 

  16. Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Medical; 2011. p. 634–89.

    Google Scholar 

  17. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278–88.

    Article  CAS  PubMed  Google Scholar 

  18. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–55.

    Article  CAS  PubMed  Google Scholar 

  19. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63:S5–21.

    Article  CAS  PubMed  Google Scholar 

  20. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30–42.

    Article  CAS  PubMed  Google Scholar 

  21. Keys A. Serum cholesterol response to dietary cholesterol. Am J Clin Nutr. 1984;40:351–9.

    Article  CAS  PubMed  Google Scholar 

  22. Abumweis SS, Barake R, Jones PJH. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008. https://doi.org/10.3402/fnr.v52i0.1811.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.

    Article  CAS  PubMed  Google Scholar 

  24. Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis. 2009;203:8–17.

    Article  CAS  PubMed  Google Scholar 

  25. Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.cd003817.pub3.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.

    Article  PubMed  Google Scholar 

  27. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93.

    Article  PubMed  Google Scholar 

  28. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. JAMA. 2006;295:2262.

    Article  CAS  PubMed  Google Scholar 

  29. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bantle JP, Raatz SK, Thomas W, Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr. 2000;72:1128–34.

    Article  CAS  PubMed  Google Scholar 

  31. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483–92.

    Article  CAS  PubMed  Google Scholar 

  33. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors. Arch Intern Med. 2006;166:285.

    Article  CAS  PubMed  Google Scholar 

  34. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–54S.

    Article  CAS  PubMed  Google Scholar 

  35. Beulens JWJ, Rimm EB, Ascherio A, Spiegelman D, Hendriks HFJ, Mukamal KJ. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med. 2007;146:10–9.

    Article  PubMed  Google Scholar 

  36. Rabkin SW. Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis: a control clinical trial. Atherosclerosis. 1984;53:173–84.

    Article  CAS  PubMed  Google Scholar 

  37. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nigović B, Mornar A, Sertic M. A review of current trends and advances in analytical methods for determination of statins: chromatography and capillary electrophoresis. In: de Azevedo Calderon L (ed) Chromatogr. Most versatile method Chem. Anal. 2012. https://doi.org/10.5772/2707.

  40. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.

    Article  CAS  PubMed  Google Scholar 

  41. Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2009;57:243–51.

    Article  CAS  Google Scholar 

  42. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74:818–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Egom EE, Rose RA, Neyses L, Soran H, Cleland JGF, Mamas MA. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit Rev Clin Lab Sci. 2013;50:79–89.

    Article  CAS  PubMed  Google Scholar 

  44. Likus W, Siemianowicz K, Bieńk K, Pakuła M, Pathak H, Dutta C, Wang Q, Shojaei S, Assaraf YG, Ghavami S, Cieślar-Pobuda A, Łos MJ. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resist Update. 2016;25:13–25.

    Article  Google Scholar 

  45. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin N Am. 1994;78:225–45.

    Article  CAS  PubMed  Google Scholar 

  46. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–95.

    Article  CAS  PubMed  Google Scholar 

  47. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–7.

    Article  CAS  PubMed  Google Scholar 

  48. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1:495–505.

    Article  CAS  PubMed  Google Scholar 

  49. Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O’Grady L, Mercuri M, Mitchel YB. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000;86:221–3.

    Article  CAS  PubMed  Google Scholar 

  50. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–60.

    Article  CAS  PubMed  Google Scholar 

  51. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475–81.

    Article  CAS  PubMed  Google Scholar 

  52. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128–33.

    Article  CAS  PubMed  Google Scholar 

  53. Dart A, Jerums G, Nicholson G, d’Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39–44.

    Article  CAS  PubMed  Google Scholar 

  54. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444–8.

    Article  CAS  PubMed  Google Scholar 

  55. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137:617–8.

    Article  PubMed  Google Scholar 

  56. Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83:687–700.

    Article  PubMed  Google Scholar 

  57. Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk. Medicine (Baltimore). 2015;94:e1268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:S52–60.

    Article  CAS  Google Scholar 

  59. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–80.

    Article  CAS  PubMed  Google Scholar 

  60. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679–86.

    Article  CAS  PubMed  Google Scholar 

  61. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27:635–62.

    Article  PubMed  Google Scholar 

  62. Jose J. Statins and its hepatic effects: newer data, implications, and changing recommendations. J Pharm Bioallied Sci. 2016;8:23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol. 2006;97:S6–26.

    Article  CAS  Google Scholar 

  64. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881–92.

    Article  CAS  PubMed  Google Scholar 

  65. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in older men. Lancet. 1993;341:75–9.

    Article  CAS  PubMed  Google Scholar 

  68. Yang C-C, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003;163:1926.

    Article  CAS  PubMed  Google Scholar 

  69. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.cd003160.pub3.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643–7.

    Article  CAS  PubMed  Google Scholar 

  71. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388–94.

    Article  CAS  PubMed  Google Scholar 

  72. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302–9.

    Article  CAS  PubMed  Google Scholar 

  73. Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92.

    Article  CAS  PubMed  Google Scholar 

  74. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90:635–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. JNCI J Natl Cancer Inst. 2006;98:69–72.

    Article  CAS  PubMed  Google Scholar 

  76. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. JNCI J Natl Cancer Inst. 2007;99:32–40.

    Article  PubMed  Google Scholar 

  77. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165:2264.

    Article  CAS  PubMed  Google Scholar 

  78. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

    Article  CAS  Google Scholar 

  79. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. JAMA. 2006;295:74.

    Article  CAS  PubMed  Google Scholar 

  80. Browning DRL, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–43.

    Article  CAS  PubMed  Google Scholar 

  81. Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering ldl cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.

    Article  CAS  Google Scholar 

  82. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–7.

    Article  CAS  PubMed  Google Scholar 

  83. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention study. N Engl J Med. 2007;357:1477–86.

    Article  CAS  PubMed  Google Scholar 

  84. Heart Protection Study Collaborative Group HPSC. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013–20.

    Article  CAS  Google Scholar 

  85. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269–75.

    Article  CAS  PubMed  Google Scholar 

  86. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol. 2004;44:904–13.

    Article  CAS  PubMed  Google Scholar 

  87. Wong V, Stavar L, Szeto L, Uffelman K, Wang CH, Fantus IG, Lewis GF. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis. 2006;184:348–55.

    Article  CAS  PubMed  Google Scholar 

  88. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, Shinomiya K, Kosaka H, Kohno M. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J. 2007;71:144–52.

    Article  CAS  PubMed  Google Scholar 

  89. Mita T, Watada H, Nakayama S, Abe M, Ogihara T, Shimizu T, Uchino H, Hirose T, Kawamori R. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J. 2007;54:441–7.

    Article  CAS  PubMed  Google Scholar 

  90. Sathyapalan T, Kilpatrick ES, Coady A-M, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94:103–8.

    Article  CAS  PubMed  Google Scholar 

  91. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63:2889–934.

    Article  PubMed  Google Scholar 

  92. Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;30:1599–610.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Cai R, Yuan Y, Sun J, Xia W, Huang R, Tian S, Dong X, Shen Y, Wang S. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert Opin Pharmacother. 2016;17:1839–49.

    Article  CAS  PubMed  Google Scholar 

  94. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Chen TJ, Lin SJ, Chiang CE. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60:1231–8.

    Article  CAS  PubMed  Google Scholar 

  95. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Rosenson RS. Statins: actions, side effects, and administration—UpToDate. n.d. https://www.uptodate.com/contents/statins-actions-side-effects-and-administration. Accessed 29 Dec 2018.

  97. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13:965–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Kasliwal RR, Bansal M, Gupta R, Shah S, Dani S, Oomman A, Pai V, Prasad GM, Singhvi S, Patel J, Sivam S, Trehan N. ESSENS dyslipidemia: a placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition. 2016;32:767–76.

    Article  CAS  PubMed  Google Scholar 

  99. Talati R, Sobieraj DM, Makanji SS, Phung OJ, Coleman CI. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc. 2010;110:719–26.

    Article  CAS  PubMed  Google Scholar 

  100. Cicero AFG, Fogacci F, Rosticci M, Parini A, Giovannini M, Veronesi M, D’Addato S, Borghi C. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab (Lond). 2017;14:61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl. 2012;9:110–5.

    Article  CAS  PubMed  Google Scholar 

  102. Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017;120:157–69.

    Article  CAS  PubMed  Google Scholar 

  103. Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076–88.

    Article  CAS  PubMed  Google Scholar 

  104. Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894–908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49:1595–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520–9.

    Article  CAS  PubMed  Google Scholar 

  108. Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ. A common PCSK9Haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005;45:1611–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.

    Article  CAS  PubMed  Google Scholar 

  110. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Am Coll Cardiol. 2010;55:2833–42.

    Article  CAS  PubMed  Google Scholar 

  111. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344–53.

    Article  CAS  PubMed  Google Scholar 

  112. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900.

    Article  CAS  PubMed  Google Scholar 

  113. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408–17.

    Article  CAS  PubMed  Google Scholar 

  114. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. JAMA. 2012;308:2497.

    Article  CAS  PubMed  Google Scholar 

  115. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995–2006.

    Article  CAS  PubMed  Google Scholar 

  117. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M, GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance. J Am Coll Cardiol. 2014;63:2541–8.

    Article  CAS  PubMed  Google Scholar 

  118. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H, MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia. J Am Coll Cardiol. 2014;63:2531–40.

    Article  CAS  PubMed  Google Scholar 

  119. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R, LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. JAMA. 2014;311:1870.

    Article  CAS  PubMed  Google Scholar 

  120. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–40.

    Article  CAS  PubMed  Google Scholar 

  121. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D’Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of proprotein convertase subtilisin/Kexin Type 9 antibodies in adults with hypercholesterolemia. Ann Intern Med. 2015;163:40.

    Article  PubMed  Google Scholar 

  122. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.

    Article  CAS  PubMed  Google Scholar 

  123. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.

    Article  CAS  PubMed  Google Scholar 

  124. Peng W, Qiang F, Peng W, Qian Z, Ke Z, Yi L, Jian Z, Chongrong Q. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: a systematic review and meta-analysis. Int J Cardiol. 2016;222:119–29.

    Article  PubMed  Google Scholar 

  125. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigator. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.

    Article  CAS  PubMed  Google Scholar 

  126. Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdullah S, Banerjee S, Brilakis ES. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017. https://doi.org/10.1161/jaha.117.006910.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–71.

    Article  CAS  PubMed  Google Scholar 

  128. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.

    Article  CAS  PubMed  Google Scholar 

  129. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–26.

    Article  CAS  PubMed  Google Scholar 

  130. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–34.

    Article  CAS  PubMed  Google Scholar 

  131. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–61.

    Article  CAS  PubMed  Google Scholar 

  132. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–8.

    Article  CAS  PubMed  Google Scholar 

  133. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.

    Article  Google Scholar 

  134. Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. Ann Intern Med. 2014;160:468.

    Article  PubMed  Google Scholar 

  135. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98:34–8.

    Article  CAS  Google Scholar 

  136. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A, Study Investigators. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs. 2009;9:91–101.

    Article  CAS  PubMed  Google Scholar 

  137. Cicero AFG, Morbini M, Bove M, D’Addato S, Fogacci F, Rosticci M, Borghi C. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Curr Med Res Opin. 2016;32:1633–8.

    Article  CAS  PubMed  Google Scholar 

  138. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.

    Article  CAS  PubMed  Google Scholar 

  139. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136–50.

    Article  CAS  PubMed  Google Scholar 

  140. Rader DJ, Brewer HB. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 1993;270:865–9.

    Article  CAS  PubMed  Google Scholar 

  141. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999–1001.

    Article  CAS  PubMed  Google Scholar 

  142. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365:65–9.

    Article  CAS  PubMed  Google Scholar 

  143. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362:906–16.

    Article  CAS  PubMed  Google Scholar 

  144. Walton KW, Scott PJ, Dykes PW, Davies JW. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci. 1965;29:217–38.

    CAS  PubMed  Google Scholar 

  145. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJP, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo (turnover/cyclohexanedione/plasma exchange/cholestyramine/l-thyroxine), vol. 78. 1981.

  146. Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun. 1990;172:1150–6.

    Article  CAS  PubMed  Google Scholar 

  147. Gullberg H, Rudling M, Saltó C, Forrest D, Angelin B, Vennström B. Requirement for thyroid hormone receptor β in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol. 2002;16:1767–77.

    Article  CAS  PubMed  Google Scholar 

  148. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.

    Article  CAS  PubMed  Google Scholar 

  149. Duell PB, Santos RD, Kirwan B-A, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016;10:1011–21.

    Article  PubMed  Google Scholar 

  150. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–40.

    Article  CAS  PubMed  Google Scholar 

  151. Inclisiran for subjects with ACSVD or ACSVD-risk equivalents and elevated low-density lipoprotein cholesterol. n.d. https://clinicaltrials.gov/ct2/show/NCT03400800?term=inclisiran&rank=4. Accessed 25 Dec 2018.

  152. Inclisiran for participants with atherosclerotic cardiovascular disease and elevated low-density lipoprotein cholesterol. n.d. https://clinicaltrials.gov/ct2/show/NCT03399370?term=inclisiran&rank=3. Accessed 25 Dec 2018.

  153. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106:1191–200.

    Article  CAS  PubMed  Google Scholar 

  154. Glueck C, Gartside P, Fallat R, Sielski J, Steiner P. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemi. J Lab Clin Med. 1976;88:941–57.

    CAS  PubMed  Google Scholar 

  155. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256–67.

    Article  PubMed  Google Scholar 

  156. Egom EE. Letter from egom regarding article, “High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy”. Circulation. 2014;2014:129.

    Google Scholar 

  157. Egom EE. HDL-C/HDL-P ratio. J Am Coll Cardiol. 2015;65:2576.

    Article  PubMed  Google Scholar 

  158. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

    Article  CAS  PubMed  Google Scholar 

  159. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.

    Article  CAS  PubMed  Google Scholar 

  160. Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–61.

    Article  CAS  PubMed  Google Scholar 

  161. Nicholls SJ, Ruotolo G, Brewer HB, Wang M-D, Liu L, Willey MB, Deeg MA, Krueger KA, Nissen SE. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016;10:519–27.

    Article  PubMed  Google Scholar 

  162. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104:984–91.

    Article  CAS  PubMed  Google Scholar 

  163. Fogacci F, Cicero AFG. Gene targeting for chylomicronemia syndrome: the brave new world. Atherosclerosis. 2018;269:254–5.

    Article  CAS  PubMed  Google Scholar 

  164. Chaudhry R, Viljoen A, Wierzbicki A. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018;11:589–98.

    Article  CAS  PubMed  Google Scholar 

  165. Ikenaga M, Higaki Y, Saku K, Uehara Y. High-density lipoprotein mimetics: a therapeutic tool for atherosclerotic diseases. J Atheroscler Thromb. 2016;23:385–94.

    Article  CAS  PubMed  Google Scholar 

  166. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292–300.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Emmanuel Eroume-A. Egom, Katarina Gazdikova, Peter Kruzliak, Ludovit Gaspar or Vincent M. G. Maher.

Ethics declarations

Conflicts of interest

Authors declare no conflict of interest.

Research involving human participants and/or animals

Not applicated, this is review paper.

Informed consent

Not applicated, this is review paper.

Additional information

Emmanuel Eroume‑A. Egom and Rebabonye B. Pharithi: co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Egom, E.EA., Pharithi, R.B., Hesse, S. et al. Latest Updates on Lipid Management. High Blood Press Cardiovasc Prev 26, 85–100 (2019). https://doi.org/10.1007/s40292-019-00306-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-019-00306-8

Keywords

Navigation